Abstract 2216P
Background
Diffuse sclerosing variant of papillary thyroid carcinoma (DSVPTC) is commonly observed in young patients, with a median age at diagnosis in the third decade of life. Further, the risk of recurrence is higher with DSVPTC than with classical papillary thyroid carcinoma (PTC). Therefore, this study aimed to describe the clinicopathological and genetic characteristics of patients of different ages with DSVPTC.
Methods
We retrospectively reviewed 397 patients who underwent thyroidectomy for DSVPTC at the Gangnam Severance Hospital, Yonsei University from January 2005 to December 2017. We selected 41 patients through random sampling by their age group, and examined mutations in 119 genes using next-generation sequencing.
Results
The mean age at diagnosis was 36.7±11.6 years, with the majority of patients (163, 41.1%) in their third decades. DSVPTC was predominant in women (276, 69.5%), compared with men. We observed recurrence in 46 patients (11.6%), with regional nodal recurrence being the most common recurrence site (32 patients, 69.6%). The tumour size increased in younger patients (<20 years: 2.69±1.56, 21–30 years: 1.88±1.30, and 31–40 years: 1.55±0.95), those displaying a plateau in their fourth (1.38±0.85) and fifth (1.29±0.91) decades, and those above 61 years of age (1.63±1.45). The initial presentation of cancer was more aggressive in paediatric patients with a larger size, more common multiplicity, and lateral neck metastasis. V-raf murine sarcoma viral oncogene homolog B1 (BRAF), Kirsten rat sarcoma virus (KRAS), and telomerase reverse transcriptase (TERT) displayed relatively higher mutations, compared with other genes.
Conclusions
DSVPTC displayed different clinical, pathological, and molecular profiles, compared with papillary thyroid carcinoma. BRAF, KRAS, and TERT were the most important genetic mutations, with differences depending on the age.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1820P - Cardiovascular effects of androgen receptor signalling inhibitors in the treatment of advanced and metastatic prostate cancer: A systematic review and meta-analysis of randomised controlled trials
Presenter: Omar El-Taji
Session: Poster session 15
1821P - High serum FSH/T ratio as a marker for the development of cardiovascular disease in ADT recipients
Presenter: Jehonathan Pinthus
Session: Poster session 15
1822P - PSMA-alpha targeted radionuclide therapy (TRT) with or without prior PSMA-beta TRT
Presenter: Michael Sun
Session: Poster session 15
1823P - The impact of baseline PSMA PET/CT vs. CT on outcomes of Radium-223 therapy in mCRPC patients
Presenter: Dianne Bosch
Session: Poster session 15
1824P - Treatment patterns among novel hormonal therapy-experienced patients with metastatic castration-resistant prostate cancer
Presenter: Vivek Narayan
Session: Poster session 15
1825P - Molecular features of circulating tumour cells (CTCs) associate with response to 177Lu-PSMA-617 plus pembrolizumab for metastatic castration resistant prostate cancer (mCRPC)
Presenter: David Goode
Session: Poster session 15
1826P - Lutetium-177-PSMA in pre- and post-taxane mCRPC setting: Results from a phase II clinical trial
Presenter: Emilio Giunta
Session: Poster session 15
1827P - Real-world (RW) overall survival (OS) with enzalutamide (ENZ) and abiraterone acetate (ABI) in patients (pts) with chemotherapy (cx)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel George
Session: Poster session 15
1828P - ARX517: A next generation anti-PSMA antibody drug conjugate (ADC) demonstrates notable stability and pharmacokinetic (PK) profile in the ARX517 phase I clinical trial (APEX-01)
Presenter: Scott Tagawa
Session: Poster session 15
1829P - Exposure-safety analyses of talazoparib in combination of enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in TALAPRO-2 trial
Presenter: Arun Azad
Session: Poster session 15